Moderna (NASDAQ:MRNA) Hits New 1-Year High at $143.87

Shares of Moderna, Inc. (NASDAQ:MRNAGet Free Report) hit a new 52-week high during trading on Tuesday . The company traded as high as $143.87 and last traded at $143.69, with a volume of 3292413 shares trading hands. The stock had previously closed at $141.01.

Analyst Ratings Changes

Several research firms have recently weighed in on MRNA. Royal Bank of Canada boosted their price objective on shares of Moderna from $125.00 to $135.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. William Blair reiterated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Evercore ISI began coverage on Moderna in a research note on Tuesday, May 14th. They issued an “in-line” rating and a $120.00 price objective on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Finally, Oppenheimer boosted their target price on Moderna from $142.00 to $163.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $126.46.

Read Our Latest Stock Report on Moderna

Moderna Stock Up 1.9 %

The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. The stock has a market cap of $55.07 billion, a P/E ratio of -9.17 and a beta of 1.57. The stock’s fifty day simple moving average is $111.36 and its 200-day simple moving average is $98.37.

Moderna (NASDAQ:MRNAGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating the consensus estimate of ($3.59) by $0.52. The firm had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company’s quarterly revenue was down 91.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.19 EPS. As a group, research analysts forecast that Moderna, Inc. will post -7.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $108.54, for a total transaction of $1,628,100.00. Following the sale, the director now owns 2,131,931 shares in the company, valued at approximately $231,399,790.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Moderna news, CFO James M. Mock sold 647 shares of the business’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the transaction, the chief financial officer now owns 4,300 shares of the company’s stock, valued at $406,651. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $108.54, for a total transaction of $1,628,100.00. Following the completion of the sale, the director now owns 2,131,931 shares in the company, valued at $231,399,790.74. The disclosure for this sale can be found here. Insiders sold 170,209 shares of company stock valued at $18,588,421 over the last quarter. 15.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Moderna during the 4th quarter valued at $27,000. Arlington Trust Co LLC boosted its stake in shares of Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after purchasing an additional 290 shares in the last quarter. Cedar Wealth Management LLC increased its stake in shares of Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares during the period. Westside Investment Management Inc. acquired a new position in shares of Moderna in the first quarter valued at approximately $32,000. Finally, Rise Advisors LLC raised its holdings in Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after buying an additional 286 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

(Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

See Also

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.